HYBRID EVENT: Join us in person in London, UK or attend virtually from anywhere.
Hepatoblastoma is a rare and aggressive Paediatric liver cancer that predominantly affects children under the age of five, making up the majority of liver Tumours in this age group. Characterized by its rapid growth and potential to metastasize, hepatoblastoma originates in the liver's immature cells, often presenting as a solitary mass or multiple nodules within the organ. While the exact etiology remains unclear, certain risk factors such as low birth weight, premature birth, and congenital conditions like Beckwith-Wiedemann syndrome have been associated with an increased susceptibility to hepatoblastoma. Clinically, patients with hepatoblastoma may exhibit symptoms such as abdominal swelling, pain, weight loss, and jaundice, which can lead to its early detection. The diagnosis typically involves a combination of imaging studies, including ultrasound, CT scans, and MRI, as well as biopsy for confirmation. Treatment strategies for hepatoblastoma are multifaceted, encompassing surgical resection, chemotherapy, and, in some cases, liver transplantation. The choice of therapy depends on factors such as the tumor's stage, size, and the patient's overall health. Prognosis varies widely, with early-stage cases often responding well to treatment, while advanced stages pose significant challenges. Collaborative efforts among healthcare professionals, researchers, and support networks play a crucial role in advancing our understanding of hepatoblastoma and improving outcomes for affected children, underscoring the importance of continued research into novel therapeutic approaches and personalized medicine for this rare Paediatric malignancy.
